Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations

Core Insights - Nuvation Bio Inc. (NUVB) is ranked seventh among the top oncology stocks to buy, highlighting its potential in the oncology sector [1] - H.C. Wainwright has lowered its price target for NUVB from $18 to $17 while maintaining a Buy rating, indicating confidence in the company's performance despite the adjustment [1][3] - Nuvation Bio reported preliminary Q4 2025 net product revenue of approximately $15.7 million for its lead asset, IBTROZI (taletrectinib), which aligns with market expectations [2][3] Financial Performance - The company reported that 216 new patients began treatment with IBTROZI in the fourth quarter, reflecting growth in patient adoption [2] - Nuvation Bio received a $25 million milestone payment from Nippon Kayaku, contributing positively to its financial position [2] Company Overview - Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology patients, particularly targeting rare and difficult-to-treat cancers [3] - The company emphasizes precision medicine and pipeline expansion to improve outcomes for patients with limited therapeutic options in oncology [3]